Compare CTM & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTM | ICCC |
|---|---|---|
| Founded | 2019 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 64.0M |
| IPO Year | 2022 | 1995 |
| Metric | CTM | ICCC |
|---|---|---|
| Price | $0.66 | $8.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 622.6K | 28.1K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.33 | 53.85 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $52,866,001.00 | $26,493,169.00 |
| Revenue This Year | $20.36 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 18.10 | ★ 51.64 |
| 52 Week Low | $0.48 | $4.52 |
| 52 Week High | $1.56 | $9.08 |
| Indicator | CTM | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 61.70 |
| Support Level | $0.63 | $5.78 |
| Resistance Level | $0.76 | N/A |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 25.27 | 50.00 |
Castellum Inc is focused on building a successful technology services, solutions, and products company in the areas of cybersecurity, IT, electronic warfare, information warfare, system modernization, and information operations with businesses in the defense, federal, civilian, and commercial markets. Services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model-based systems engineering. The company maintains one operating and reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.